Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Commvault Systems Inc (CVLT) Price & Performance

Citius Pharmaceuticals IncTrade
Commvault Systems IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Commvault Systems Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.68 (market cap $20.01M), while Commvault Systems Inc trades at $140.06 (market cap $5.78B). The key difference: Commvault Systems Inc is far larger — about 288.9× Citius Pharmaceuticals Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRCVLT
Market Cap
$20.01M$5.78B
Sector
HealthTechnology
52-Week High
$1.82$195.41
52-Week Low
$0.48$75.18
Enterprise Value
$16.23M$5.76B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Commvault Systems Inc

Commvault Systems (CVLT) trades at $139.36, down slightly by 0.05% on the day, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $1.42 surpassing the $1.16 estimate. Recent positive developments include the integration of Threat Scan with Google Threat Intelligence and a partnership with Microsoft for AI security on Azure, driving investor optimism despite a shareholder investigation announcement.

CVLT presents a mixed fundamental picture with robust revenue growth and strong profitability metrics but elevated valuation multiples. The stock offers significant upside to the consensus price target of $172.40, supported by 54.5% analyst buy ratings. Key risks include high P/E ratio of 89.35, ongoing fiduciary investigation, and potential margin compression as revenue growth outpaces net income growth in 2026 projections.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT